TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-blind, Placebo-controlled, Single Bolus, Multinational, Multi-center, Parallel Group, Dose-ranging Study of Desmoteplase (INN) in the Indication of Acute Stroke
Brief Summary: The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic stroke.


Options:
A: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Intervention Type: DRUG; Name: Alteplase t-PA; Assigned to Arm(s): N/A
D: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-blind, Placebo-controlled, Single Bolus, Multinational, Multi-center, Parallel Group, Dose-ranging Study of Desmoteplase (INN) in the Indication of Acute Stroke
Brief Summary: The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic stroke.


Options:
A: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
C: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: tenecteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tissue plasminogen activator, tPA | Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tissue plasminogen activator, tPA; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Exercise in Lymphoma Patients
Brief Summary: Objectives: The primary objective of this trial is to determine the effect of aerobic exercise training (AET) on change in quality of life (QoL) in lymphoma survivors receiving and not receiving chemotherapy. Secondary objectives are to determine the effects of AET on changes in psychosocial outcomes, cardiopulmonary fitness, body composition, and treatment completion rates.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Exercise
B: Arm Label: Standard PA Recommendation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telephone Implementation Intention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Implementation Intention | Arm Label: Self-completed implementation intention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-completed implementation intention | Intervention Type: BEHAVIORAL; Name: Telephone Implementation Intention; Assigned to Arm(s): Telephone Implementation Intention | Intervention Type: BEHAVIORAL; Name: Self-completed implementation intention; Assigned to Arm(s): Self-completed implementation intention
C: Arm Label: Exercise based multimodal intervention; Type: EXPERIMENTAL; Interventions: Other: Exercise based multimodal intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise based multimodal intervention; Assigned to Arm(s): Exercise based multimodal intervention
D: Arm Label: Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Rehabilitation Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation Program; Assigned to Arm(s): Rehabilitation Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Exercise in Lymphoma Patients
Brief Summary: Objectives: The primary objective of this trial is to determine the effect of aerobic exercise training (AET) on change in quality of life (QoL) in lymphoma survivors receiving and not receiving chemotherapy. Secondary objectives are to determine the effects of AET on changes in psychosocial outcomes, cardiopulmonary fitness, body composition, and treatment completion rates.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Exercise
B: Arm Label: Exercise based multimodal intervention; Type: EXPERIMENTAL; Interventions: Other: Exercise based multimodal intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise based multimodal intervention; Assigned to Arm(s): Exercise based multimodal intervention
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
D: Arm Label: Telephone Counselling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counselling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telephone counselling; Assigned to Arm(s): Telephone Counselling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study of Neoadjuvant Chemotherapy Followed by Interval Cytoreductive Surgery for Stage III/IV Ovarian, Tubal and Peritoneal Cancers: JCOG0206
Brief Summary: A feasibility study of neoadjuvant chemotherapy (NAC) followed by interval cytoreductive surgery (ICS) and postoperative chemotherapy for stage III/IV mullerian carcinomas such as ovarian, tubal and peritoneal carcinomas.


Options:
A: Arm Label: Arm I PDS and chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDS (Primary Debulkdung Surgery), Procedure: 6 cycles of standard chemotherapy | Arm Label: Arm II Timing of surgery after 3 cycles of SOC CTX; Type: EXPERIMENTAL; Interventions: Procedure: Timing of surgery after 3 cycles of standard NACT, IDS, Procedure: IDS, Drug: 3 cycles of standard chemotherapy | Intervention Type: PROCEDURE; Name: PDS (Primary Debulkdung Surgery); Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: 6 cycles of standard chemotherapy; Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: Timing of surgery after 3 cycles of standard NACT, IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: PROCEDURE; Name: IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: DRUG; Name: 3 cycles of standard chemotherapy; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX
B: Arm Label: Primary debulking surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary Debulking Surgery + Adjuvant Chemotherapy | Arm Label: Interval debulking surgery; Type: EXPERIMENTAL; Interventions: Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery | Intervention Type: DRUG; Name: Neoadjuvant chemotherapy + Interval Debulking Surgery; Assigned to Arm(s): Interval debulking surgery | Intervention Type: PROCEDURE; Name: Primary Debulking Surgery + Adjuvant Chemotherapy; Assigned to Arm(s): Primary debulking surgery
C: Intervention Type: DRUG; Name: Neoadjuvant chemotherapy (Paclitaxel and Carboplatin); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Phase II Clinical Trial of Activated Protein C (Xigris) Versus Placebo for the Treatment of Acute Lung Injury
Brief Summary: The purpose of this study is to test the efficacy of activated Protein C (Xigris) for improving clinical outcomes in individuals with acute lung injury (ALI).


Options:
A: Arm Label: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Assigned to Arm(s): Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
B: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A
C: Arm Label: Human Mesenchymal Stromal Cells (hMSCs); Type: EXPERIMENTAL; Interventions: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells | Arm Label: Plasma-Lyte A (placebo); Type: PLACEBO_COMPARATOR; Interventions: Biological: Plasma-Lyte A | Intervention Type: BIOLOGICAL; Name: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells; Assigned to Arm(s): Human Mesenchymal Stromal Cells (hMSCs) | Intervention Type: BIOLOGICAL; Name: Plasma-Lyte A; Assigned to Arm(s): Plasma-Lyte A (placebo)
D: Intervention Type: DRUG; Name: Xigris; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quitlink : A Leveraging Solution to Tobacco Counseling
Brief Summary: Primary: To test whether the delivery of A3-5 smoking cessation counseling (Assess, Assist, Arrange) in primary care offices is enhanced by a system that couples (1) an expanded vital sign intervention with (2) fax referral of preparation-stage patients for telephone counseling and (3) feedback to the provider. The question will be examined in a randomized trial, with practices as the unit of analysis and with a control intervention consisting of a conventional vital sign intervention. The experiment will therefore compare what intervention and control practices accomplish beyond simply identifying patients who use tobacco.

Secondary: To assess contextual factors that might affect implementation of the intervention and account for its ultimate success or failure. In particular, to assess: (1) environmental and practice-level factors that affect practices' ability to successfully implement and use the intervention and; (2) patient characteristics beyond readiness to change (i.e., age, gender, race/ethnicity) that affect willingness to use the quit line and complete counseling.


Options:
A: Intervention Type: BEHAVIORAL; Name: QuitLink (office support system for quit line referral); Assigned to Arm(s): N/A
B: Arm Label: social cognitive theory; Type: EXPERIMENTAL; Interventions: Behavioral: Social Cognitive Theory | Arm Label: Goal Systems Theory; Type: EXPERIMENTAL; Interventions: Behavioral: goal system theory | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Social Cognitive Theory; Assigned to Arm(s): social cognitive theory | Intervention Type: BEHAVIORAL; Name: goal system theory; Assigned to Arm(s): Goal Systems Theory
C: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedicine | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Telemedicine | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quitlink : A Leveraging Solution to Tobacco Counseling
Brief Summary: Primary: To test whether the delivery of A3-5 smoking cessation counseling (Assess, Assist, Arrange) in primary care offices is enhanced by a system that couples (1) an expanded vital sign intervention with (2) fax referral of preparation-stage patients for telephone counseling and (3) feedback to the provider. The question will be examined in a randomized trial, with practices as the unit of analysis and with a control intervention consisting of a conventional vital sign intervention. The experiment will therefore compare what intervention and control practices accomplish beyond simply identifying patients who use tobacco.

Secondary: To assess contextual factors that might affect implementation of the intervention and account for its ultimate success or failure. In particular, to assess: (1) environmental and practice-level factors that affect practices' ability to successfully implement and use the intervention and; (2) patient characteristics beyond readiness to change (i.e., age, gender, race/ethnicity) that affect willingness to use the quit line and complete counseling.


Options:
A: Intervention Type: BEHAVIORAL; Name: QuitLink (office support system for quit line referral); Assigned to Arm(s): N/A
B: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Care for Smoking Cessation in PTSD patients | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Integrated Care for Smoking Cessation in PTSD patients; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Arm 2
D: Arm Label: CBP + PF; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Current Best Practices (CBP) | Arm Label: CBP + PF + P4P; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Financial Incentive (P4P), Behavioral: Current Best Practices (CBP) | Arm Label: Current Best Practices (CBP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Current Best Practices (CBP) | Intervention Type: BEHAVIORAL; Name: Audit and performance feedback (PF); Assigned to Arm(s): CBP + PF, CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Financial Incentive (P4P); Assigned to Arm(s): CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Current Best Practices (CBP); Assigned to Arm(s): CBP + PF, CBP + PF + P4P, Current Best Practices (CBP)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the TRIUMPH Trial
Brief Summary: Tilarginine Acetate Injection is a new type of drug that temporarily stops the body from making a bodily substance called nitric oxide. The body may produce excess nitric oxide following severe heart damage leading to shock. During a heart attack, and especially after a blocked artery causing the heart attack is reopened, a large amount of nitric oxide is released into the heart muscle and into the blood. Normally small amounts of nitric oxide are good for the heart and blood vessels. However, when released in large amounts, such as during a heart attack, it may be harmful, by adding to the damage of the heart attack and lowering the heart's ability to pump blood to the body. It may cause blood pressure to be lowered and reduce the amount of blood flow to the body's vital organs. This may interfere with the body's organs being able to do their work. If Tilarginine Acetate Injection can stop extra nitric oxide from being made, the performance of the heart and blood flow to the organs may get better, which may result in the improvement of symptoms. The purpose of this study (TRIUMPH) is to investigate the safety and effectiveness of Tilarginine Acetate Injection compared to placebo (an inactive fluid that has no effect on the body but looks exactly like the medication being studied). The study will help determine whether Tilarginine Acetate Injection, by temporarily lowering the amount of nitric oxide released into the vital organs can improve blood pressure and the blood flow to the body's organs.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: levosimendan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo,; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Tilarginine Acetate Injection intravenous infusion; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dobutamine; Assigned to Arm(s): N/A
D: Arm Label: Intraaortic balloon pump; Type: ACTIVE_COMPARATOR; Interventions: Device: Intraaortic balloon pump | Arm Label: No intraaortic balloon pump; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Intraaortic balloon pump; Assigned to Arm(s): Intraaortic balloon pump

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary Pseudomonas Aeruginosa (AIR-CF1)
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).


Options:
A: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
B: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
C: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)
D: Arm Label: Morning dose of tobramycin; Type: ACTIVE_COMPARATOR; Interventions: Other: Tobramycin time of administration | Arm Label: Evening tobramycin; Type: ACTIVE_COMPARATOR; Interventions: Other: Tobramycin time of administration | Intervention Type: OTHER; Name: Tobramycin time of administration; Assigned to Arm(s): Evening tobramycin, Morning dose of tobramycin

Answer: C